

FORM PTO-1449

U.S. Dept. of Commerce  
Patent and Trademark Office

Atty Docket No.

P1256R3

Serial No.

09/209,023

## LIST OF DISCLOSURES CITED BY APPLICANT

(Use several sheets if necessary)

MAR 15 1999

Applicant

Paton et al.

Filing Date

10 Dec 1998

Group

1643

## U.S. PATENT DOCUMENTS

Examiner Initials		Document Number	Date	Name	Class	Subclass	Filing Date
(JN)	1	5,359,046	25.10.94	Capon et al.			
(JN)	2	5,578,482	26.11.96	Lippman et al.			

## FOREIGN PATENT DOCUMENTS

Examiner Initials		Document Number	Date	Country	Class	Subclass	Translation Yes	No
(JN)	3	WO 89/06692	27.07.89	PCT				
(JN)	4	WO 94/00136	06.01.94	PCT				
(JN)	5	WO 94/22478	13.10.94	PCT				

## OTHER DISCLOSURES (Including Author, Title, Date, Pertinent Pages, etc.)

(JN)	6	Arteaga et al., "p185C-erbB-2 signaling enhances cisplatin-induced cytotoxicity in human breast carcinoma cells: association between an oncogenic receptor tyrosine kinase and drug-induced DNA repair" <u>Cancer Research</u> 54(14):3758-3765 (Jul 15, 1994)					
(JN)	7	Bacus et al., "Differentiation of cultured human breast cancer cells (AU-565 and MCF-7) associated with loss of cell surface HER-2/neu antigen" <u>Molecular Carcinogenesis</u> 3(6):350-362 (1990)					
(JN)	8	Bacus et al., "Tumor-inhibitory monoclonal antibodies to the HER-2/Neu receptor induce differentiation of human breast cancer cells" <u>Cancer Research</u> 52(9):2580-2589 (May 1, 1992)					
(JN)	9	Baselga et al., "Anti HER2 Humanized Monoclonal Antibody (Mab) Alone and in Combination with Chemotherapy Against Human Breast Carcinoma Xenografts" <u>Proceedings of ASCO-13th Annual Meeting</u> (Abstract #53), Dallas, TX 13:63 (Mar 1994)					
(JN)	10	Baselga et al., "HER2 overexpression and paclitaxel sensitivity in breast cancer: therapeutic implications" <u>Oncology</u> 11(3 Suppl 2):43-48 (Mar 1997)					
(JN)	11	Baselga et al., "Phase II Study of Weekly Intravenous Recombinant Humanized Anti-p185HER2 Monoclonal Antibody in Patients With HER2/neu-Overexpressing Metastatic Breast Cancer" <u>J. Clin. Oncol.</u> 14(3):737-744 (1996)					
(JN)	12	Carter et al., "Humanization of an anti-p185HER2 antibody for human cancer therapy" <u>Proc. Natl. Acad. Sci.</u> 89:4285-4289 (1992)					
(JN)	13	D'souza et al., "Overexpression of ERBB2 in human mammary epithelial cells signals inhibition of transcription of the E-cadherin gene" <u>Proc. Natl. Acad. Sci. USA</u> 91(15):7202-7206 (Jul 19, 1994)					
(JN)	14	DiFiore et al., "erbB-2 is a potent oncogene when overexpressed in NIH/3T3 cells" <u>Science</u> 237(4811):178-182 (Jul 10, 1987)					
(JN)	15	Drebin et al., "Down-Modulation of and Oncogene Protein Product an Reversion of the Transformed Phenotype by Monoclonal Antibodies" <u>Cell</u> 41(3):695-706 (1985)					
(JN)	16	Drebin et al., "Inhibition of tumor growth by a monoclonal antibody reactive with an oncogene-encoded tumor antigen" <u>Proc. Natl. Acad. Sci.</u> 83:9129-9133 (1986)					
(JN)	17	Drebin et al., "Monoclonal antibodies reactive with distinct domains of the neu oncogene-encoded p185 molecule exert synergistic anti-tumor effects in vivo" <u>Oncogene</u> 2:273-277 (1988)					
(JN)	18	Drebin et al., "Monoclonal Antibodies Specific for the neu Oncogene Product Directly Mediate Anti-tumor Effects In Vivo" <u>Oncogene</u> 2(4):387-394 (1988)					
(JN)	19	Fendly et al., "Characterization of Murine Monoclonal Antibodies Reactive to Either the Human Epidermal Growth Factor Receptor or HER2/neu Gene Product" <u>Cancer Research</u> 50:1550-1558 (March 1, 1990)					

Examiner


Jennifer Nichols nee Hunt

Date Considered

1/03/2000

\*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

FORM PTO-1449		U.S. Dept. of Commerce Patent and Trademark Office		Atty Docket No. P1256R3	Serial No. 09/209,023
<b>LIST OF DISCLOSURES CITED BY APPLICANT</b> (Use several sheets if necessary)				Applicant Paton et al.	
				Filing Date 10 Dec 1998	Group 1643
<b>OTHER DISCLOSURES (Including Author, Title, Date, Pertinent Pages, etc.)</b>					
(jn)	20	Fleiss, JL <u>Statistical Methods for Rates and Proportions</u> , 2nd edition, New York, NY:Wiley pps. 13-17 (1981)			
(jn)	21	Green et al., "Preclinical Evaluation of WR-151327: An Orally Active Chemotherapy Protector" <u>Cancer Research</u> 54(3):738-741 (Feb 1, 1994)			
(jn)	22	Guy et al., "Expression of the neu protooncogene in the mammary epithelium of transgenic mice induces metastatic disease" <u>Proc. Natl. Acad. Sci. USA</u> 89(22):10578-10582 (Nov 15, 1992)			
(jn)	23	Hancock et al., "A Monoclonal Antibody Against the c-erbB-2 Protein Enhances the Cytotoxicity of cis-Diamminedichloroplatinum Against Human Breast and Ovarian Tumor Cell Lines" <u>Cancer Research</u> 51:4575-4580 (September 1, 1991)			
(jn)	24	Harwerth et al., "Monoclonal antibodies against the extracellular domain of the erbB-2 receptor function as partial ligand agonists" <u>Journal of Biological Chemistry</u> 267(21):15160-15167 (Jul 1992)			
(jn)	25	Hudziak et al., "Increased expression of the putative growth factor receptor p185HER2 causes transformation and tumorigenesis of NIH 3T3 cells" <u>Proc. Natl. Acad. Sci.</u> 84:7159-7163 (1987)			
(jn)	26	Hudziak et al., "p185HER2 Monoclonal Antibody Has Antiproliferative Effects In Vitro and Sensitizes Human Breast Tumor Cells to Tumor Necrosis Factor" <u>Molecular &amp; Cellular Biology</u> 9(3):1165-1172 (1989)			
(jn)	27	Hynes and Stern, "The biology of erbB-2/neu/HER-2 and its role in cancer" <u>Biochimica et Biophysica Acta</u> 1198(2-3):165-184 (Dec 30, 1994)			
(jn)	28	Kasprzyk et al., "Therapy of an animal model of human gastric cancer using a combination of anti-erbB-2 monoclonal antibodies" <u>Cancer Research</u> 52(10):2771-2776 (May 15, 1992)			
(jn)	29	Kotts et al., "Differential growth inhibition of human carcinoma cells exposed to monoclonal antibodies directed against the extracellular domain of the HER2/ERBB2 protooncogene" <u>In Vitro</u> (Abstract #176) 26(3):59A (1990)			
(jn)	30	Kumar et al., "Regulation of phosphorylation of the c-erbB-2/HER2 gene product by a monoclonal antibody and serum growth factor(s) in human mammary carcinoma cells" <u>Molecular &amp; Cellular Biology</u> 11(2):979-986 (Feb 1991)			
(jn)	31	Lewis et al., "Differential Responses of Human Tumor Cell Lines to Anti-p185HER2 Monoclonal Antibodies" <u>Cancer Immunol. Immunother.</u> 37:255-263 (1993)			
(jn)	32	Maier et al., "Requirements for the internalization of a murine monoclonal antibody directed against the HER-2/neu gene product c-erbB-2" <u>Cancer Research</u> 51(19):5361-5369 (Oct 1, 1991)			
(jn)	33	McKenzie et al., "Generation and characterization of monoclonal antibodies specific for the human neu oncogene product, p185" <u>Oncogene</u> 4:543-548 (1989)			
(jn)	34	Myers et al., "Biological Effects of Monoclonal Antireceptor Antibodies Reactive with neu Oncogene Product, p185neu" <u>Methods in Enzymology</u> 198:277-290 (1991)			
(jn)	35	Norton, L, "Evolving concepts in the systemic drug therapy of breast cancer" <u>Seminars in Oncology</u> 24(4 Suppl 10):S10-3-S10-10 (Aug 1997)			
(jn)	36	Pietras et al., "Antibody to HER-2/neu Receptor Blocks DNA Repair After Cisplatin in Human Breast and Ovarian Cancer Cells" <u>Oncogene</u> 9:1829-1838 (1994)			
(jn)	37	Ravdin and Chamness, "The c-erbB-2 proto-oncogene as a prognostic and predictive marker in breast cancer: a paradigm for the development of other macromolecular markers--a review" <u>Gene</u> 159(1):19-27 (Jun 14, 1995)			
(jn)	38	Sarup, "Characterization of an Anti-P185HER2 Monoclonal Antibody that Stimulates Receptor Function and Inhibits Tumor Cell Growth" <u>Growth Regulation</u> 1:72-82 (1991)			
(jn)	39	Scott et al., "p185HER2 signal transduction in breast cancer cells" <u>Journal of Biological Chemistry</u> 266(22):14300-14305 (Aug 5, 1991)			
Examiner		Jennifer Nichols nee Hunt		Date Considered 1/03/2000	
*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.					

FORM PTO-1449		U.S. Dept. of Commerce Patent and Trademark Office 		Atty Docket No. P1256R3	Serial No. 09/209,023
<b>LIST OF DISCLOSURES CITED BY APPLICANT</b> (Use several sheets if necessary)				Applicant Paton et al.	
				Filing Date 10 Dec 1998	Group 1643
<b>OTHER DISCLOSURES (Including Author, Title, Date, Pertinent Pages, etc.)</b>					
(m)	40	Seifert et al., "Dexrazoxane in the prevention of doxorubicin-induced cardiotoxicity" <u>Annals of Pharmacotherapy</u> 28(9):1063-1072 (Sep 1994)			
(m)	41	Shawver et al., "Ligand-like effects induced by anti-c-erbB-2 antibodies do not correlate with and are not required for growth inhibition of human carcinoma cells" <u>Cancer Research</u> 54(5):1367-1373 (Mar 1, 1994)			
(m)	42	Shepard et al., "Monoclonal Antibody Therapy of Human Cancer: Taking the HER2 Protooncogene to the Clinic" <u>J. Clin. Immunol.</u> 11(3):117-127 (1991)			
(m)	43	Singal and Iliskovic, "Doxorubicin-induced cardiomyopathy" <u>New England J. of Medicine</u> 339(13):900-905 (Sep 24, 1998)			
(m)	44	Singal et al., "Combination therapy with probucol prevents adriamycin-induced cardiomyopathy" <u>Journal of Molecular &amp; Cellular Cardiology</u> 27(4):1055-1063 (Apr 1995)			
(m)	45	Slamon et al., "Human Breast Cancer: Correlation of Relapse and Survival with Amplification of the HER-2/neu Oncogene" <u>Science</u> 235:177-182 (1987)			
(m)	46	Slamon, et al., "Studies of the HER-2/neu Proto-oncogene in Human Breast and Ovarian Cancer" <u>Science</u> 244:707-712 (May 1989)			
(m)	47	Sliwkowski et al., "Coexpression of erbB2 and erbB3 proteins reconstitutes a high affinity receptor for heregulin" <u>Journal of Biological Chemistry</u> 269(20):14661-14665 (1994)			
(m)	48	Stancovski et al., "Mechanistic aspects of the opposing effects of monoclonal antibodies to the ERBB2 receptor on tumor growth" <u>Proc. Natl. Acad. Sci. USA</u> 88(19):8691-8695 (Oct 1, 1991)			
(m)	49	Tagliabue et al., "Selection of monoclonal antibodies which induce internalization and phosphorylation of p185 <sup>HER2</sup> and growth inhibition of cells with HER2/NEU gene amplification" <u>International Journal of Cancer</u> 47(6):933-937 (Apr 1, 1991)			
(m)	50	Vitetta et al., "Monoclonal antibodies as agonists: an expanded role for their use in cancer therapy" <u>Cancer Research</u> 54(20):5301-5309 (Oct 15, 1994)			
(m)	51	Xu et al., "Antibody-induced growth inhibition is mediated through immunochemically and functionally distinct epitopes on the extracellular domain of the c-erbB-2 (HER- 2/neu) gene product p185" <u>International Journal of Cancer</u> 53(3):401-408 (Feb 1, 1993)			
Examiner		Jennifer Nichols nee Hunt		Date Considered 1/03/2000	

\*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

FORM PTO-1449

U.S. Dept. of Commerce  
Patent and Trademark Office

**Case Docket No.**  
P1256R3

Serial No.  
09/209,023

**LIST OF DISCLOSURES CITED BY APPLICANT**



(Use several sheets if necessary)

Applicant  
Paton et al.


Filing Date  
10 Dec 1998

Group	1643
-------	------

## U.S. PATENT DOCUMENTS

Examiner Initials		Document Number	Date	Name	Class	Subclass	Filing Date
	1	5,677,171	14.10.97	Hudziak et al.			
	2	5,705,157	06.01.98	Greene			

## FOREIGN PATENT DOCUMENTS

Examiner Initials	Document Number	Date	Country	Class	Subclass	Translation Yes No	
	3 WO 97/20858	12.06.97	PCT				

**OTHER DISCLOSURES** (Including Author, Title, Date, Pertinent Pages, etc.)

[illegible]

Examiner

Jennifer Nichols nee Hunt

Date Considered

1/03/2000

\*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.